CRLのチャート
CRLの企業情報
| symbol | CRL |
|---|---|
| 会社名 | Charles River Laboratories International Inc. （CHRLS RIVER LABS） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | チャールズ・リバー・ラボラトリーズ・インターナショナル(Charles River Laboratories International Inc.)は初期段階の創薬と開発プロセスを促進するソリューションを提供する。同社は生体内生物学を中心に事業を展開する。同社のポートフォリオは生体内薬物の発見と開発を支援する研究モデル・サービスを含む。同社は研究モデル・サービス（RMS）区分及び前臨床サービス（PCS）区分の2事業区分を通して運営する。同社はRMS区分を通して、薬剤開発業界向けに研究モデルを提供している。同社は遺伝学的と微生物学的に定義された目的に繁殖されたラット及びマウスを主とする齧歯類の研究モデル系統の生産と販売に従事する。PCS事業区分は依頼人向けに、規制を必要とする安全性評価と関連薬剤開発業務のアウトソーシングサービスを提供する。平成24年8月、同社はAccugenix Incを買収した。平成25年1月、同社はVital Riverの持分の75％を取得した。 チャ―ルズ・リバ―・ラボラトリ―ズ・インタ―ナショナルは、迅速で効率的な新薬創出の実現をサポ―ト。新薬の研究開発から承認までのプロセスに必要な標的探索から臨床試験まで一括提供。事業は研究サ―ビスと前臨床サ―ビスの2部門。サ―ビスは、受託試験、受託飼育、医薬品、化学品、農薬等の受託サ―ビスなど。また、実験動物、研究試薬を生産、販売する。 Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. |
| 本社所在地 | 251 Ballardvale Street Wilmington MA 01887 USA |
| 代表者氏名 | James C. Foster |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 781-222-6000 |
| 設立年月日 | 1994年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 14700人 |
| url | www.criver.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 519.91300 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 6939.76800 |
| 売上高 | （百万ドル） 2266.09600 |
| 企業価値(EV) | （百万ドル） 8411.45500 |
| 当期純利益 | （百万ドル） 219.36700 |
| 決算概要 | BRIEF: For the fiscal year ended 29 December 2018 Charles River Laboratories Intl. Inc revenues increased 22% to $2.27B. Net income before extraordinary items increased 9% to $219.4M. Revenues reflect Discovery And Safety Assessment segment increase of 34% to $1.32B Manufacturing Support segment increase of 12% to $429.6M Research Models segment increase of 5% to $519.7M United States segment increase of 32% to $1.27B. |
CRLのテクニカル分析
CRLのニュース
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference 2023/01/09 21:15:00 Business Wire
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital 2023/01/05 16:20:39 Seeking Alpha
Charles River Laboratories (CRL) has sold its Avian Vaccine Services business to private equity firm Arlington Capital Partners.The business, now AVS Bio, will operate independently as…
Clinical Trials Market Worth $52.0 Billion, Global Update, Share Analysis, Leading Players, Business Opportunities, Forecast by 2026 2022/12/15 16:16:00 SBWire
In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants. Northbrook, IL 60062 -- ( SBWIRE ) -- 12/15/2022 -- The Global Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026" published by MarketsandMarkets, the clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as growing R&D expenditure, increasing outsourcing of R&D activities, and the rising number of clinical trials worldwide are driving the growth of the global clinical trials market. The growing biosimilars and biologics market, rising demand for specialized testing services, and emerging Asian markets also offer significant growth opportunities for players operating in the market.
CRL stock gains as Cambodia denies restrictions on monkey exports (NYSE:CRL) 2022/12/15 15:12:05 Seeking Alpha
Charles River Laboratories (CRL) added ~7% Thursday after Cambodia dismissed reports of restrictions on its exports of monkeys for medical research. Read the full story here.
Stem Cell Assay Global Market Report 2022: Ukraine-Russia War Impact 2022/12/12 11:33:00 GlobeNewswire
Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc. Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc.
US stock market closes higher, Dow Jones gains 2.18% 2022/12/01 02:40:18 InstaForex
At the close of the New York Stock Exchange, the Dow Jones rose 2.18% to a 6-month high, the S&P 500 rose 3.09% and the NASDAQ Composite index rose 4.41%. The leading gainers among the components of the Dow Jones index today were shares of Microsoft Corporation, which gained 14.81 points (6.16%) to close at 255.14. Salesforce Inc rose 8.57 points or 5.65% to close at 160.25. Apple Inc rose 4.86% or 6.86 points to close at 148.03. The least gainers were Walmart Inc, which shed 0.55 points or 0.36% to end the session at 152.42. 3M Company rose 0.13% or 0.16 points to close at 125.97, while Caterpillar Inc rose 0.55% or 1.29 points to close at 236.41 . Leading gainers among the S&P 500 index components in today''s trading were Estee Lauder Companies Inc (NYSE:EL), which rose 9.70% to 235.79, Netflix Inc, which gained 8.75% to close at 305.53, as well as shares of Hewlett Packard Enterprise Co, which rose 8.57% to close the session at 16.79. The least gainers were NetApp Inc, which shed 5.82% to close at 67.61.
Challenges to Cambodia monkey supply causes Charles River Laboratories International in US to fall 2022/11/30 21:29:30 Khmer Times
Shares of Charles River Laboratories International Inc. fell in morning trading Wednesday after the non-clinical contract research company warned that supplies of Cambodia-sourced monkeys will likely be challenging for some period of time. The post Challenges to Cambodia monkey supply causes Charles River Laboratories International in US to fall appeared first on Khmer Times .
Charles River Laboratories and Labcorp shares fall on potential NHP supply issues By Investing.com 2022/11/30 18:30:20 Investing.com
Charles River Laboratories and Labcorp shares fall on potential NHP supply issues
CRL stock drops after disclosing supply challenges for animal studies (NYSE:CRL) 2022/11/30 17:40:12 Seeking Alpha
Charles River Laboratories (CRL) was among notable decliners in the S&P 500 on Wednesday after the non-clinical contract research organization announced that a recent DoJ indictment…
Charles River Laboratories: Price Discovery (NYSE:CRL) 2022/11/21 13:45:23 Seeking Alpha
After Charles River’s quick and strong recovery in recent weeks, should investors take profits or hold? Read more to see a full analysis of CRL stock.
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call 2022/10/11 20:30:00 Kwhen Finance
Benzinga''s Top Ratings Upgrades, Downgrades For September 30, 2022 2022/09/30 14:37:05 Benzinga
Upgrades According to TD Securities, the prior rating for Brookfield Renewable Partners LP (NYSE: BEP ) was changed from Buy to Action List Buy. Brookfield Renewable earned $0.03 in the second quarter, compared to $0.13 in the year-ago quarter. The current stock performance of Brookfield Renewable shows a 52-week-high of $41.95 and a 52-week-low of $30.85. Moreover, at the end of the last trading period, the closing price was at $30.94. Citigroup upgraded the previous rating for Agnico Eagle Mines Ltd (NYSE: AEM ) from Neutral to Buy. In the second quarter, Agnico Eagle Mines showed an EPS of $0.75, compared to $0.69 from the year-ago quarter. At the moment, the stock has a 52-week-high of $67.14 and a 52-week-low of $36.69. Agnico Eagle Mines closed at $41.43 at the end of the last trading period. For Bed Bath & Beyond Inc (NASDAQ: BBBY ), Odeon Capital upgraded the previous rating of Sell to Hold. In the second quarter, Bed Bath & Beyond showed an EPS of $3.22, compared to $0.04 from the year-ago quarter.
''Right Now, You''ve Still Got To Avoid The Stock,'' Jim Cramer Says About This Aerospace Company 2022/09/30 14:10:43 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW ) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. When asked about Charles River Laboratories International, Inc. (NYSE: CRL ), Cramer said, "It finally doesn’t have a high price-to-earnings multiple. I would actually start … Full story available on Benzinga.com